Another of many, many examples of the danger of using stop loss orders.
Look at how many shares got taken out below 255, and now over 270!!!!!
May also want to check out the crmd board on Investor Village, many very sophisticated investors with med backgrounds as well. Many have the ability to look deeply behind the press releases and cut to the real meat very quickly.
Anytime we get a chance to see more data, it could get exciting!
"We are excited to be presenting new OCA clinical data in both PBC and NASH patients," said Mark Pruzanski, M.D., Chief Executive Officer of Intercept. "Furthermore, the Global PBC Study Group and UK-PBC Group analyses will provide the hepatology community with additional scientific insights into potential treatment goals for patients with PBC. This is timely as we prepare for the anticipated launch of OCA in the U.S. and Europe next year."
Yeah, I get to it by going to the mess. board of any other symbol, then just type icpt in the box titled "Get message board for:" It's a royal pain, but works.
Can't get to it by first looking at the chart or news etc, have to get to it by going from another mess. board.
I've been following this "deceptive" mgmt team for quite awhile now, and they have done everything they said they would. Not sure of the exact timeframe, no one is, but they will be sold!
Short away, we appreciate the additional fuel.
that this company will be sold shortly. Very unusual to see this type of verbage right on a company's own website, but there it is:
If you go to their website, look under News & Press, first line is an article titled, CoreMedix Overview April 2015, go to page 6.
As part of its publicly announced exploration of strategic alternatives to accelerate the global development of Neutrolin® Catheter Lock Solution and maximize shareholder value, CorMedix Inc. (“CorMedix” or the “Company”) is soliciting indications of interest to acquire 100% of the stock of the Company.
That very well may be preparations underway for raising money if required, based on the filings of late.
BUT, if you go to their website, look under News & Press, first line is article titled CoreMedix Overview April 2015, go to page 6.
As part of its publicly announced exploration of strategic alternatives to accelerate the global development of Neutrolin® Catheter Lock Solution and maximize shareholder value, CorMedix Inc. (“CorMedix” or the “Company”) is soliciting indications of interest
to acquire 100% of the stock of the Company.
Well, what do ya know, the company is up for sale!!!!!!
Do some DD, and you won't look and sound so stupid.
In a research note issued today, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) with a $493 price target, as the company is expected to present two late-breaking presentations at the the International Liver Congress 2015 of the European Association for the Study of the Liver (EASL), which will take place April 22-26, 2015 at Reed Messe, Vienna, Austria.
If you did a fair amount of DD, you wouldn't be asking questions with such obvious answers.
Do some homework, then come back with legit questions and many people, including myself would be more than happy to help you.